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DNA methylation-based biomarkers, often referred to 
as “epigenetic age” or "epigenetic clock", are robust 
estimators of chronological age of an individual [1–4]. 
For example, a measure of epigenetic age based on 
levels of methylation in 353 CpG dinucleotide markers 
(cytosine linked to guanine by a phosphate group) 
allow the estimation of the age of an individual. This 
estimate is consistent across most types of biological 
specimens, including whole blood, brain, breast, 
kidney, liver, lung, and saliva and cell types, including 
CD4+ T cells, monocytes, B cells, glial cells, and 
neurons [3]. 
 
Recent studies suggested that epigenetic age is associated 
with age-related health outcomes above and beyond 
chronological age. For example, we and others have 
shown that individuals whose epigenetic age was greater 
than their chronological age (i.e., individuals exhibiting 
epigenetic "age acceleration") were at an increased risk 
for death from all causes, even after accounting for 
known risk factors [5–7]. Further, we recently showed 
that the offspring of semi-supercentenarians (subjects 
who reached an age of 105-109 years) have a lower 
epigenetic age than age-matched controls [8]. Based on 
these findings, it has been hypothesized that epigenetic 
age captures some aspect of biological age and the 
resulting susceptibility to disease and multiple health 
outcomes. A first step in testing this hypothesis is to test 
whether epigenetic age predicts longevity in multiple 
populations and across ethnic groups. 
 
In many studies epigenetic age is estimated from DNA 






















cell composition changes with age and some of these 
changes might be independent predictors of mortality [9–
12]. Thus, it is of interest to understand whether 
considering information on blood cell composition in 
measures of epigenetic age improves their predictive 
power for mortality. 
 
Here, we evaluated the ability to predict time to death 
for blood-based epigenetic age measures, both 
published and novel measures that incorporate 
information on blood cell composition. Due to the well 
documented age-related changes in blood cell 
composition, we distinguished epigenetic measures of 
age that were independent of changes in blood cell 
composition (cell-intrinsic measures), and measures that 
incorporated age-related changes in blood cell 
composition ("extrinsic" measures). By increasing the 
number of independent cohort studies, we more than 
doubled the number of mortality events available for 
analysis, which allowed for detailed subgroup analyses 






Our meta-analysis included 13 population-based 
cohorts. An overview of the cohorts is provided in 
Table 1. Our study involved 3 racial/ethnic groups: non-
Hispanic whites (n=9,215), Hispanics (n=431), and 
Blacks (n=3,443). Detailed descriptions of each cohort 
can be found in the Supplemental Materials. 
  




age",  have  been  shown  to  be  robust  biomarkers  of  age  in  humans.  We  previously  demonstrated  that
independent of chronological age, epigenetic age assessed in blood predicted all‐cause mortality in four human
cohorts. Here, we expanded our original observation to 13 different cohorts for a total sample size of 13,089
individuals,  including three racial/ethnic groups. In addition, we examined whether  incorporating  information
on blood  cell  composition  into  the epigenetic age metrics  improves  their predictive power  for mortality. All
considered measures of epigenetic age acceleration were predictive of mortality (p≤8.2x10‐9),  independent of
chronological  age,  even  after  adjusting  for  additional  risk  factors  (p<5.4x10‐4),  and within  the  racial/ethnic
groups  that we examined  (non‐Hispanic whites, Hispanics, African Americans). Epigenetic age estimates  that
incorporated information on blood cell composition led to the smallest p‐values for time to death (p=7.5x10‐43).





Epigenetic age estimation 
 
We used two methods for estimating the epigenetic age  
of each blood sample (Table 2). First, we used the 
approach by Horvath (2013) based on 353 CpGs, as 
described in [3] and Methods. Second, we used the 
approach by Hannum et al. (2013) based on 71 CpGs 
[2]. Both epigenetic age estimates were correlated with 
chronological age at the time of blood draw (Table 1) 
with biweight midcorrelation coefficients ranging from 
0.65 to 0.89. But birth cohorts were excluded from this 
correlation analysis because it is not meaningful to 
calculate correlations with chronological age in this 
situation. The Horvath and Hannum estimates were also 
highly correlated with each other (r=0.76) even though 
the underlying sets of CpGs share only 6 CpGs in 







































Estimated blood cell counts that relate to 
chronological age 
 
We estimated the abundance of ten blood cell types based 
on observed DNA methylation patterns (Methods) –
exhausted/senescent CD8+ T cells (CD8+CD28-
CD45RA-), CD8+ naïve, CD8+ total, CD4+ naïve, 
CD4+ total, natural killer cells, B cells, monocytes, 
granulocytes, and plasmablasts. To study age-related 
changes in blood cell composition, we correlated these 
estimated blood cell counts with chronological age in all 
of the cohort studies (Supplementary Table 2). Our 
results are congruent with findings from flow cytometric 
studies that demonstrate that the abundance of naïve 
CD8+ T cells decreases with age (reflecting thymic 
involution), whereas exhausted/senescent CD8+ T cells 












































rHorvath† rHannum ‡ 
1. WHI (White) 995 309 (31%) 15.4 (14.0-16.4) 68 (65-72) 0.67 (p=5.1x10-131) 0.73 (p=8.0x10-167) 
2. WHI (Black) 675 176 (26%) 15.4 (13.7-16.5) 62 (57-67) 0.70 (p=1.2x10-100) 0.76 (p=3.0x10-128) 
3. WHI (Hispanic) 431 78 (18%) 15.2 (14.1-16.3) 61 (56-67) 0.78 (p=8.9x10-90) 0.79 (p=1.3x10-93) 
4. LBC 1921 445 312 (70%) 10.2 (6.2-12.9) 79 (78-79) 0.15 (p=1.5x10-3) 0.13 (p=6.0x10-3) 
5. LBC 1936 919 106 (12%) 7.5 (6.9-8.4) 69 (68-70) 0.15 (p=4.9x10-6) 0.16 (p=1.1x10-6) 
6. NAS 647 221 (34%) 11.6 (8.6-12.9) 72 (68-77) 0.69 (p=1.3x10-92) 0.76 (p=8.2x10-123) 
7. ARIC (Black) 2,768 1,075 (39%) 20.3 (14.3-21.4) 57 (52-62) 0.65 (p<1x10-200) 0.71 (p<1x10-200) 
8. FHS 2,614 236 (9%) 6.2 (5.6-6.9) 66 (60-73) 0.84 (p<1x10-200) 0.86 (p<1x10-200) 
9. KORA 1,257 42 (3%) 4.4 (4.0-4.8) 61 (54-68) 0.84 (p<1x10-200) 0.88 (p<1x10-200) 
10. InCHIANTI 506 91 (18%) 15.0 (14.6-15.5) 67 (57-73) 0.82 (p=3.2x10-124) 0.85 (p=2.1x10-142) 
11. Rotterdam 710 32 (5%) 5.6 (5.3-5.8) 58 (54-62) 0.72 (p=1.9x10-114) 0.76 (p=1.3x10-134) 
12.Twins UK 805 30 (4%) 8.5 (7.5-8.5) 58 (51-65) 0.87 (p<1x10-200) 0.89 (p<1x10-200) 
13. BLSA (white) 317 26 (8%) 5.3 (4.0-6.6) 66 (58-73) 0.85 (p=1.1x10-89) 0.88 (p=7.2x10-104) 
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Measures of epigenetic age acceleration 
 
Despite high correlations, epigenetic age can deviate 
substantially from chronological age at the individual 



















































nological age can be used to define "delta age" but the 
resulting measure exhibits a negative correlation with 
chronological age. By contrast, all of our measures of 
epigenetic age acceleration are defined such that they 

































































(Universal) epigenetic age acceleration  AgeAccelHorvath 
(AgeAccel) 
Horvath: 353 CpGs no weak  yes




Horvath: 353 CpGs yes very weak  yes
Age acceleration based on Hannum  AgeAccelHannum Hannum: 71 CpGs no moderate  no
Intrinsic epigenetic age acceleration 
(Hannum) 
IEAA.Hannum Hannum: 71 CpGs yes very weak  no
Extrinsic epigenetic age acceleration  EEAA  Enhanced Hannum yes strong          no
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An overview of several measures of epigenetic age 
acceleration is presented in Table 2. One such measure 
(denoted as AgeAccel) is defined as the residual that 
results from regressing epigenetic age on chronological 
age. Thus, a positive value of AgeAccel indicates that the 
epigenetic age is higher than expected, based on 
chronological age. These Horvath and Hannum based 
measures of age acceleration are denoted by 
AgeAccelHorvath and AgeAccelHannum, respectively. For the 
sake of brevity and consistency with other publications 
from our group, we abbreviate AgeAccelHorvath as 
AgeAccel. 
 
AgeAccelHannum and to a lesser extent AgeAccel were 
previously shown to correlate with blood cell counts 
[5]. Thus, we distinguished two broad categories of 
measures of epigenetic age acceleration when dealing 
with DNA methylation from blood or peripheral blood 
mononuclear cells (PBMCs): intrinsic and extrinsic 
epigenetic measures, which are independent of, or 
enhanced by blood cell count information, respectively. 
We define intrinsic epigenetic age acceleration (IEAA) 
as the residual resulting from regressing epigenetic age 
on chronological age and measures of blood cell counts 
(Methods). By definition, IEAA is not correlated with 
chronological age and is weakly correlated with 
estimated measures of blood cell counts (Supplementary 
Table 4). IEAA is meant to capture cell-intrinsic 


























servation across various cell types and organs. 
Compared to our other measures of age acceleration, 
IEAA, adapted from the Horvath measure of epigenetic 
age, exhibited significant correlations with epigenetic 
age acceleration in breast tissue (r=0.48, p=0.0011, 
Figure 1B) and saliva (r=0.67, p=8.8x10-9, Figure 1F). 
By contrast, an analogous measure of IEAA based on 
the Hannum measure showed much weaker correlations 
(r=0.073 in breast and r=0.41 in saliva Figure 1D, 1H). 
For this reason, we focused on the Horvath measure of 
IEAA. 
 
The age-related changes to blood cell composition 
(Supplementary Table 4) can be leveraged to capture 
aspects of immunosenescence. Using these measures, 
we derived a novel extrinsic epigenetic age acceleration 
(EEAA) measure by up-weighting the blood cell count 
contributions of AgeAccelHannum (Methods and 
Supplementary Table 4). 
 
Descriptive statistics (minimum, maximum, median) of 
the measures of epigenetic age acceleration can be 
found in Supplementary Table 3. 
 
Cox regression models of all-cause mortality 
 
We used Cox regression models to assess the predictive 
value of our measures of epigenetic age acceleration for 




































www.aging‐us.com                  1849                                                       AGING (Albany NY)
for the age at baseline (blood draw). Additional 
multivariate models further adjusted for covariates 




















































educational level, alcohol intake, smoking pack-years, 
prior history of diabetes, prior history of cancer, hyper-























































used  to relate  the censored survival  time  (time  to all‐cause mortality)  to  (A)  the universal measure of age acceleration  (AgeAccel),  (B)
intrinsic  epigenetic  age  acceleration  (IEAA),  (C)  extrinsic  epigenetic  age  acceleration  (EEAA).  The multivariate  Cox  regression model
included the following additional covariates: chronological age, body mass index (category), educational level (category), alcohol intake,
smoking pack years, prior history of diabetes, prior history of cancer, hypertension status, recreational physical activity (category). The
rows correspond  to  the different cohorts. Each  row depicts  the hazard  ratio and a 95% confidence  interval. The coefficient estimates
from the respective studies were meta‐analyzed using a fixed‐effect model weighted by inverse variance (implemented in the metafor R
package [34]). The sub‐title of each plot reports the meta‐analysis p‐value and a heterogeneity test p‐value (Cochran's Q‐test). 





















































































































































Figure  4.  Hazard  ratio  of  death  versus  cohort  characteristics.  Each  circle  corresponds  to  a  cohort  (data  set).  Circle  sizes
correspond  to  the square  root of  the number of observed deaths, because  the statistical power of a Cox model  is determined by  the
number of observed deaths. (A‐C) The y‐axis of each panel corresponds to the natural log of the hazard ratio (ln HR) of a univariate Cox
regression model for all‐cause mortality. Each panel corresponds to a different measure of epigenetic age acceleration (A) universal age
acceleration,  (B)  intrinsic  age  acceleration,  (C)  extrinsic  age  acceleration.  Panels  (D‐F)  are  analogous  to  those  in  A‐C  but  the  x‐axis





















































































































 Age-adjusted   Full model  
Subgroup HR p-value   HR p-value  
Race        
White 1.05 3.0x10-26   1.03 1.3x10-5  
Black 1.04 7.8x10-20   1.02 7.6x10-3 
Hispanic 1.05 1.1x10-2   1.06 5.3x10-2  
pinteraction  0.62    0.14  
        
Sex        
Men 1.04 7.1x10-15   1.03 1.9x10-2  
Women 1.04 3.7x10-10   1.03 1.9x10-5  
pinteraction  0.63    0.95  
        
Follow-up 
duration 
       
<5 years 1.02 0.20   0.98 0.79  
5-10 years 1.02 1.8x10-3   1.02 0.17  
>10 years 1.03 4.5x10-9   1.02 4.1x10-2  
pinteraction  0.67    0.84  
        
BMI 
categories 
       
Underweight 1.11 9.4x10-3   1.04 8.9x10-3  
Normal 1.06 6.1x10-19   1.04 2.3x10-2  
Overweight 1.04 1.46x10-8   1.03 5.0x10-2  
Obese 1.04 2.2x10-11   1.02 7.1x10-2  
pinteraction  0.05    0.75  
        
Smoking status        
Never 1.03 6.9x10-6   1.04 4.8x10-3  
Former 1.05 4.2x10-22   1.03 6.3x10-4  
Current 1.06 2.1x10-4   1.01 0.47  
pinteraction  0.05    0.20  
        
Physical 
activity status 
       
Yes 1.05 3.8x10-6   1.02 1.9x10-3  
No 1.03 2.5x10-2   1.03 2.2x10-2  
pinteraction  0.23    0.65  
        
Age‐adjusted  and  fully  adjusted  associations  for  EEAA  to  all‐
cause mortality by  subgroup  (rows). The  fully  adjusted model 
includes the following covariates: body mass index, educational 
level,  alcohol  intake,  smoking  pack‐years,  prior  history  of 
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Our novel measure of extrinsic age acceleration EEAA 
led to smaller p-values for the associations with all-cause 
mortality than the original measure AgeAccelHannum in 
univariate Cox models (pEEAA=7.5x10-43, 
pAgeAccelHannum=1.4x10-34, Supplementary Figure 1) and in 
multivariate Cox models (pEEAA=3.4x10-19, 
pAgeAccelHannum=6x10-15, Supplementary Figure 2). Further, 
when both EEAA and AgeAccelHannum were included in 
the same Cox model, only EEAA remained significant in 
the WHI data and FHS univariate models. Since these 
results indicate that EEAA outperforms the closely related 
measure AgeAccelHannum when it comes to mortality 
prediction, we removed the latter from subsequent 
analyses. 
 
All considered measures of epigenetic age acceleration 
were predictive of time to death in univariate Cox 
models (pAgeAccel=1.9x10-11, pIEAA=8.2x10-9, 
pEEAA=7.5x10-43, Figure 2) and multivariate Cox models 
adjusting for risk factors and pre-existing disease status 


































Interpreting effect sizes and variance of epigenetic 
age acceleration 
 
Subjects differed substantially in terms of their 
measures of epigenetic age acceleration, e.g. EEAA 
ranged from -28 to 28 years in the WHI (standard 
deviation =6.4 years, Supplementary Table 3). 
 
About five percent of the participants of the WHI 
exhibited an EEAA value larger than 10, which is 
associated with a 48% increased hazard of death as can 
be seen from the following calculation. The HR of 
EEAA is 1.040 if EEAA=1 (Figure 2c) but it is 
HR=1.48=(1.040)10 if EEAA=10. Negative values of 
age acceleration were associated with a lower hazard of 
mortality. For example, 20% of subjects had an EEAA 
value less than -5, which is associated with an 18% 




With few exceptions, we found that the associations 


































 Age-adjusted   Full model  
Subgroup HR p-value   HR p-value  
Cancer status        
Yes 1.05 2.5x10-10   1.02 0.18  
No 1.05 2.3x10-13   1.03 1.7x10-4  
pinteraction  0.92    0.73  
        
Coronary artery 
disease status 
       
Yes 1.04 2.4x10-5   1.01 0.60  
No 1.04 1.5x10-12   1.02 1.5x10-4  
pinteraction  0.43    0.99  
        
Hypertension status        
Yes 1.04 7.4x10-17   1.03 2.9x10-3  
No 1.05 7.1x10-6   1.02 8.6x10-3  
pinteraction  0.41    0.45  
        
Type 2 diabetes status        
Yes 1.04 8.6x10-13   1.03 1.7x10-3  
No 1.04 1.2x10-10   1.02 9.3x10-3  
pinteraction  0.70    0.25  
Age‐adjusted  and  fully  adjusted  associations  for  EEAA  to  all‐cause 
mortality  in  different  subgroups  (rows).  The  fully  adjusted  model 
includes the  following covariates: body mass  index, educational  level, 
alcohol  intake,  smoking  pack‐years,  prior  history  of  diabetes,  prior 
history  of  cancer,  hypertension  status,  self‐reported  recreational 
physical activity. 
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ficant in subgroups stratified by race, sex, follow-up 
duration, body mass index, smoking status, physical 
activity (Table 3) and in subgroups stratified by 
prevalent disease at baseline such as cancer, coronary 
artery disease, hypertension and type 2 diabetes (Table 
4). Only one subgroup led to an insignificant finding 
(p>0.05) in our univariate model analysis: namely 
subjects with less than 5 years of follow up (Table 3). 
For multivariate models, we failed to observe 
significant associations for the following subgroups: i) 
less than 5 years of follow up, ii) between 5 and 10 
years of follow up, iii) current smokers, iv) obese 
individuals, v) Hispanics, vi) individuals with cancer, 
and vii) subjects with coronary artery disease. The 
insignificant results in multivariate models in cancer 
patients or CAD patients might reflect the relatively low 
sample sizes or that epigenetic age acceleration is 
dwarfed by other predictors of mortality in subjects with 
severe diseases. Hazard ratio estimates remained highly 
consistent across all subgroups examined. 
 
We did not observe significant differences in the 
estimated hazard ratios across any subgroup (Tables 3 
and 4). Specifically, racial/ethnic differences in HR 
were not observed (interaction p=0.62 in age-
adjustment models and p=0.14 in full models). Overall, 
these subgroup analysis results confirm that epigenetic 
age acceleration is an independent predictor of earlier 
mortality even after adjusting for possible confounders 
and within major subgroups of the population. 
 
Hazard ratio of death versus follow up time and 
median age 
 
The large number of cohorts allowed us to relate cohort 
characteristics (such as median age or median follow up 
removing time) to strength of association with 
mortality. We did not find a statistically significant 
relationship between the hazard ratio of death for the 





To assess the robustness of our findings, we also carried 
out a leave-one-out analysis by re-running the 
metaanalysis after removing data from individual 
cohorts. The resulting p-values are highly robust with 
respect to a single data set from the analysis 
(Supplementary Table 5). In our study, we used a fixed 
effects meta-analysis method for the sake of consistency 
with previous analyses [5]. However, our results remain 
qualitatively the same after using a random effects 
meta-analysis method (Supplementary Figure 4). 
DISCUSSION 
 
The current study corroborates previous findings 
regarding the predictive power of DNA methylation-
based biomarkers of age for mortality [5,6,8]. We 
further examined novel variants of these measures that 
are either independent of blood cell counts or are 
enhanced by changes in blood cell sub-populations. We 
showed that the extrinsic measure EEAA out-performs 
previous measures of age acceleration when it comes to 
predicting all-cause mortality. Furthermore, the 
associations between epigenetic age acceleration and 
mortality did not differ significantly across subgroups 
of race/ethnicity, sex, BMI, smoking status, physical 
activity status, or major chronic diseases. The 
consistency of the associations across multiple 
subgroups lends support to the notion that epigenetic 
age acceleration captures some aspect of biological 
aging over and above chronological age and other risk 
factors. 
 
The development of suitable measures of biological age 
has been a key goal in the field of aging research [13]. 
Many biomarkers of age have been posited including 
epigenetic alterations of the DNA (e.g., DNA 
methylation), transcriptomic changes in blood [14], 
telomere length [15], whole-body function such as gait 
speed (reviewed in [16]). The current study does not 
aim to replace existing blood based biomarkers, but 
rather, we aimed to demonstrate that it complements 
existing markers. Above all, this study shows that 
epigenetic age captures an aspect of biological age, as 
assessed through lifespan, above and beyond 
chronological age, blood cell composition, and a host of 
traditional risk factors of mortality. 
 
The measures of epigenetic age acceleration are 
attractive because they are highly robust and because 
their measurement only involve DNA methylation data. 
While actual flow cytometry data will always be 
preferable to imputed blood cell count data (based on 
DNA methylation data), the measures of age 
acceleration do not require the measurement of flow 
data. Rather, measures of intrinsic and extrinsic 
epigenetic age used blood cell count estimates resulting 
from DNA methylation data. The measure of extrinsic 
age acceleration EEAA reflects aspects of immuno-
senescence because, by construction, it correlates with 
age-related changes in blood cell composition, such as 
T lymphocyte populations, which underlie much of the 
age-related decline in the protective immune response 
[9–12]. Thus, the high predictive significance of EEAA 
for all-cause mortality probably reflects the fact that it 
assesses multiple aspects of the biological age of the 
immune system including both changes in blood cell 
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composition and cell-intrinsic epigenetic changes. It has 
been known for decades that poor T cell functioning is 
predictive of mortality [17]. 
 
The findings surrounding the predictive utility of 
intrinsic epigenetic age acceleration are biologically 
compelling and point to a new frontier in aging 
research. Our study strongly suggests IEAA is reflective 
of an intrinsic epigenetic clock that is associated with 
mortality independent of chronological age, changes in 
blood cell composition, and traditional risk factors of 
mortality. IEAA probably captures a cell-type 
independent component of the aging process for the 
following reasons. First, IEAA is moderately preserved 
across different tissues and cell types collected from the 
same subject (Figure 1). Second, IEAA but not EEAA is 
predictive of lung cancer [18]. Third, only IEAA and 
AgeAccel relate to centenarian status [8]. 
 
Overall, our results inform the ongoing debate about 
whether epigenetic biomarkers of age capture an aspect 
of biological age. While epigenetic processes are 
unlikely to be the only mediators of chronological age 
on mortality—in fact, multiple risk factors have 
stronger effects on mortality—our results suggest that at 
least one of the mediating processes relates to the 
epigenetic age of blood tissue and that this process is 
independent of age-dependent changes in blood cell 
composition. Future studies will be useful for gaining a 
mechanistic understanding of this intrinsic epigenetic 
aging process. 
 
MATERIALS AND METHODS 
 
Measures of epigenetic age 
 
We used an epigenetic biomarker of age based on 353 
CpG markers as one measure of epigenetic age because: 
a) it is an accurate measurement of age across multiple 
tissues [3]; b) we previously showed that it is predictive 
of all-cause mortality [5]; c) it correlated with measures 
of cognitive/physical fitness and neuro-pathology in the 
elderly [19,20]; and d) it was associated with conditions 
that are of interest in aging research including Down's 
syndrome [21], Huntington's disease [22], Parkinson's 
disease [23], obesity [24], HIV infection [25], 
menopause [26], centenarian status [27], ethnicity and 
sex [28], and cellular senescence [3,29]. This epigenetic 
age estimator not only lends itself to measuring aging 
effects in elderly subjects; but also applies to prenatal 
brain samples [30] and blood samples from minors [31]. 
Epigenetic age is defined as the predicted value of age 
based on the DNA methylation levels of 353 CpGs. 
Mathematical details and software tutorials for 
estimating epigenetic age can be found in the additional 
files of [3]. All of the described epigenetic measures of 
aging and age acceleration are implemented in our 
freely available software (https://dnamage.genetics. 
ucla.edu) [3]. 
 
DNA methylation age estimate by Hannum et al 
(2013) 
 
We also used an alternative measure of epigenetic age 
developed by Hannum et al (2013) [2]. The resulting 
age estimate is based on the 71 CpGs and coefficient 
values from the third supplementary table [2]. The 
authors developed this age prediction method by using 
an elastic net regression model for predicting 
chronological age based on DNA methylation levels 
from whole blood. 
 
Measures of epigenetic age acceleration 
 
Table 2 provides an overview of our measures of 
epigenetic age acceleration. The universal measure of 
age acceleration (AgeAccel), which is valid for a wide 
range of tissue types, is defined as the residual resulting 
from a linear regression model that regresses the 
Horvath estimate of epigenetic age on chronological 
age. Thus, a positive value for AgeAccel indicates that 
the observed epigenetic age is higher than that 
predicted, based on chronological age. AgeAccel has a 
relatively weak correlation with blood cell counts [25], 
but it still relates to estimated blood cell counts, as seen 
in Supplementary Table 4. 
 
To estimate "pure" epigenetic aging effects that are not 
influenced by differences in blood cell counts 
("intrinsic" epigenetic age acceleration, IEAA), we 
obtained the residual resulting from a multivariate 
regression model of epigenetic age on chronological age 
and various blood immune cell counts (naive CD8+ T 
cells, exhausted CD8+ T cells, plasmablasts, CD4+ T 
cells, natural killer cells, monocytes, and granulocytes) 
imputed from methylation data. 
 
Extrinsic epigenetic age acceleration measures capture 
both cell intrinsic methylation changes and extracellular 
changes in blood cell composition. Our measure of 
EEAA is defined using the following three steps. First, 
we calculated the epigenetic age measure from Hannum 
et al [2], which already correlated with certain blood 
cell types [5]. Second, we increased the contribution of 
immune blood cell types to the age estimate by forming 
a weighted average of Hannum’s estimate with 3 cell 
types that are known to change with age: naïve 
(CD45RA+CCR7+) cytotoxic T cells, exhausted 
(CD28-CD45RA-) cytotoxic T cells, and plasmablasts 
using the Klemera-Doubal approach [32]. The weights 
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used in the weighted average are determined by the 
correlation between the respective variable and 
chronological age [32]. The weights were chosen on the 
basis of the WHI data. Thus, the same (static) weights 
were used for all data sets. EEAA was defined as the 
residual variation resulting from a univariate model 
regressing the resulting age estimate on chronological 
age. By construction, EEAA is positively correlated with 
the estimated abundance of exhausted CD8+ T cells, 
plasmablast cells, and a negative correlated with naive 
CD8+ T cells. Blood cell counts were estimated based 
on DNA methylation data as described in the next 
section. By construction, the measures of EEAA track 
both age related changes in blood cell composition and 
intrinsic epigenetic changes. None of our four measures 
of epigenetic age acceleration are correlated with 
chronological age. 
 
Estimating blood cell counts based on DNA 
methylation levels 
 
We estimate blood cell proportions using two different 
software tools. Houseman's estimation method [33], 
which is based on DNA methylation signatures from 
purified leukocyte samples, was used to estimate the 
proportions of cytotoxic (CD8+) T cells, helper (CD4+) 
T, natural killer, B cells, and granulocytes. The software 
does not allow us to identify the type of granulocytes in 
blood (neutrophil, eosinophil, or basophil) but we note 
that neutrophils tend to be the most abundant 
granulocyte (~60% of all blood cells compared with 
0.5-2.5% for eosinophils and basophils). To estimate the 
percentage of exhausted CD8+ T cells (defined as 
CD28-CD45RA-), plasmablasts, and the number 
(count) of naïve CD8+ T cells (defined as 
CD45RA+CCR7+), we used the "Horvath method" 
[25], which is implemented in the advanced analysis 
option of the epigenetic age calculator software [3]. We 
and others have shown that imputed blood cell counts 
have moderately high correlations with corresponding 
flow cytometric data, e.g. r=0.86 for naïve CD4+ T 
cells, r=0.68 for naïve CD8+T, and r=0.49 for 
exhausted CD8+ T cells [28]. 
 
Cox regression models and meta-analysis 
 
Here, we used Cox models for analyzing the censored 
survival time data (from the age at blood draw until age 
at death or last follow-up). We regressed the censored 
survival times on covariates using Cox regression 
models implemented in the R function coxph in the 
survival package. The resulting coefficient values 
(interpreted as log hazard ratios) and standard errors 
were combined using the R software package metafor 
[34]. The meta-analysis was carried out with the R 
command rma (with arguments method="FE" to get 
fixed effects estimates). The forest plots were created 
using the R function forest (with argument atransf=exp 




In addition to cohort-specific quality checks, we further 
excluded individuals who had ever been diagnosed with 
leukemia (ICD-9: 203-208), reported receiving 
chemotherapy, and whose methylation beta value 
distributions deviated substantially from a gold standard 
(according to the quality statistic corSampleVSgold 
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Age Epigenetic age (Horvath)  
Epigenetic age 
(Hannum) 
      
Age 
  




0.74 - 0.76 
Epigenetic age 
(Hannum) 















cells B cells Monocytes Granulocytes 
ARIC 0.03 0.16 -0.22 -0.13 -0.06 -0.08 0.13 -0.08 0.09 0.04 
FHS 0.23 0.36 -0.38 -0.22 -0.19 -0.23 0.20 -0.27 0.17 0.16 
InCHIANTI 0.06 0.32 -0.43 -0.34 -0.19 -0.20 0.23 -0.20 0.08 0.11 
KORA 0.20 0.48 -0.53 -0.37 -0.07 -0.37 0.12 -0.22 0.20 0.16 
LBC1921 0.03 0.03 -0.14 -0.09 0.10 0.01 0.05 -0.07 0.10 -0.07 
LBC1936 0.11 0.04 -0.05 -0.09 -0.03 0.00 -0.05 -0.13 -0.09 0.05 
NAS 0.04 0.28 -0.21 -0.07 0.01 -0.16 0.12 -0.10 -0.01 0.08 
RSIII 0.11 0.20 -0.26 -0.16 -0.10 -0.14 0.06 -0.16 0.14 0.11 
TwinsUK -0.02 0.21 -0.35 -0.08 -0.14 0.07 0.27 -0.02 0.10 -0.14 
WHI White 0.09 0.21 -0.17 -0.13 -0.13 -0.10 0.17 -0.12 0.10 0.04 
WHI Black 0.12 0.24 -0.21 -0.13 -0.07 -0.17 0.16 -0.18 0.11 0.07 
WHI 
Hispanic 0.08 0.26 -0.21 -0.15 -0.11 -0.13 0.17 -0.10 0.03 0.08 



































































































































AgeAccel ARIC 5.081 -34.380 -3.191 -0.100 3.220 25.620 
AgeAccel FHS 4.621 -16.490 -3.110 -0.367 2.460 35.160 
AgeAccel InCHIANTI 4.999 -33.600 -3.084 -0.338 2.223 29.770 
AgeAccel KORA 4.937 -24.810 -3.423 -0.117 2.905 20.660 
AgeAccel LBC1921 6.971 -24.240 -3.884 -0.170 3.943 39.730 
AgeAccel LBC1936 6.485 -30.160 -3.879 0.116 3.801 42.100 
AgeAccel NAS 5.365 -16.930 -3.706 -0.498 2.909 32.830 
AgeAccel RSIII 6.003 -18.570 -4.325 -0.046 4.276 20.050 
AgeAccel TwinsUK 4.108 -13.760 -2.514 0.274 2.899 13.560 
AgeAccel WHI (white) 5.153 -22.560 -2.843 -0.103 3.443 22.790 
AgeAccel WHI (Black) 6.091 -21.900 -5.424 -1.977 1.824 39.930 
AgeAccel WHI (Hispanic) 4.494 -14.080 -3.831 -0.535 2.458 14.790 
AgeAccel BLSA 4.828 -11.620 -2.966 0.290 3.197 25.180 
AgeAccel ARIC 5.914 -38.770 -3.766 0.105 3.648 39.350 
        
AgeAccelHannum FHS 5.279 -23.480 -3.303 -0.174 3.001 36.680 
AgeAccelHannum InCHIANTI 6.028 -43.640 -3.152 0.431 3.573 31.490 
AgeAccelHannum KORA 4.996 -30.280 -3.266 -0.314 2.711 37.410 
AgeAccelHannum LBC1921 7.203 -25.140 -4.574 -0.821 3.722 51.840 
AgeAccelHannum LBC1936 6.670 -27.520 -4.172 0.131 4.183 31.650 
AgeAccelHannum NAS 5.161 -12.250 -3.310 -0.787 2.511 22.750 
AgeAccelHannum RSIII 6.090 -18.600 -3.825 0.115 4.152 17.970 
AgeAccelHannum TwinsUK 5.246 -17.040 -2.949 0.320 3.821 20.260 
AgeAccelHannum WHI (white) 5.557 -23.460 -3.644 -0.086 3.441 21.760 
AgeAccelHannum WHI (Black) 6.317 -23.490 -4.773 -0.891 3.045 31.480 
AgeAccelHannum WHI (Hispanic) 5.357 -12.740 -2.139 1.133 4.469 20.880 
AgeAccelHannum BLSA 5.709 -15.720 -2.942 0.429 3.801 31.730 
AgeAccelHannum ARIC 4.928 -34.020 -3.010 -0.057 3.068 23.810 
        
IEAA FHS 4.491 -16.010 -2.901 -0.199 2.547 32.160 
IEAA InCHIANTI 4.783 -30.930 -2.898 -0.374 2.364 29.470 
IEAA KORA 4.647 -29.350 -3.276 -0.114 2.761 18.740 
IEAA LBC1921 6.228 -22.890 -3.664 0.135 3.554 24.600 
IEAA LBC1936 6.162 -26.310 -3.596 0.035 3.718 34.090 
IEAA NAS 4.929 -24.190 -3.019 -0.458 2.694 22.500 
IEAA RSIII 5.130 -16.610 -3.330 -0.026 3.387 15.190 
IEAA TwinsUK 4.016 -14.590 -2.257 0.234 2.718 13.100 





























































































































counts estimated  from DNA methylation profiles  (rows) and  several measures of  epigenetic age acceleration 
(columns). 
 
  AgeAccel IEAA EEAA AgeAccelHannum IEAA.Hannum 
BloodCell average r (SE) average r (SE) average r (SE) average r (SE) average r (SE) 
Plasma Blast 0.02 (0.031) 0 (0.002) 0.28 (0.034) 0.20 (0.033) 0 (0.018) 
Exhausted CD8+ 0.18 (0.039) 0 (0.009) 0.50 (0.033) 0.29 (0.044) 0 (0.046) 
CD8.naive -0.18 (0.043) 0 (0.011) -0.52 (0.04) -0.35 (0.048) 0 (0.05) 
CD4.naive -0.09 (0.033) 0.07 (0.017) -0.36 (0.038) -0.28 (0.041) 0.06 (0.046) 
CD8T 0.19 (0.026) 0 (0.023) 0 (0.046) 0 (0.041) -0.01 (0.024) 
CD4T -0.20 (0.032) 0 (0.004) -0.46 (0.034) -0.34 (0.036) 0 (0.026) 
NK 0.13 (0.026) 0 (0.002) 0.17 (0.042) 0.10 (0.042) 0 (0.03) 
Bcell -0.08 (0.051) -0.11 (0.028) -0.05 (0.068) -0.01 (0.061) -0.02 (0.035) 
Monocyte 0.05 (0.026) 0 (0.006) 0.12 (0.042) 0.07 (0.04) 0 (0.019) 






IEAA WHI (Black) 5.588 -20.320 -3.202 0.067 3.197 42.660 
IEAA WHI (Hispanic) 4.333 -13.520 -3.971 -1.397 1.864 12.480 
IEAA BLSA 4.488 -10.370 -2.658 0.017 3.330 23.120 
        
EEAA ARIC 6.673 -32.940 -4.096 0.135 4.149 38.560 
EEAA FHS 5.800 -26.100 -3.607 0.113 3.315 38.250 
EEAA InCHIANTI 6.710 -44.360 -3.327 0.576 4.236 33.630 
EEAA KORA 5.405 -26.610 -3.526 -0.339 3.189 37.600 
EEAA LBC1921 7.745 -21.180 -5.262 -0.973 4.306 52.120 
EEAA LBC1936 7.116 -30.590 -4.439 0.168 4.589 31.530 
EEAA NAS 5.596 -13.730 -3.443 -0.579 2.987 23.540 
EEAA RSIII 6.861 -22.380 -4.392 0.267 4.794 21.080 
EEAA TwinsUK 5.840 -22.790 -3.409 0.401 4.023 23.020 
EEAA WHI (white) 6.089 -22.710 -3.888 0.015 4.008 22.320 
EEAA WHI (Black) 6.906 -27.600 -5.735 -1.382 2.827 27.900 
EEAA WHI (Hispanic) 5.779 -14.310 -1.679 2.371 5.651 23.450 
EEAA BLSA 6.256 -18.040 -3.435 0.921 4.724 29.230 
  






























































































































Cohort removed Age-adjusted model Fully adjusted model 
(None) 1.04 (p=1.81x10-42) 1.02 (p=1.94x10-7) 
ARIC 1.04 (p=1.00x10-26) 1.03 (p=1.09x10-6) 
FHS 1.04 (p=1.23x10-34) 1.02 (p=5.09x10-6) 
LBC 1921 1.04 (p=1.17x10-38) 1.02 (p=3.21x10-6) 
LBC 1936 1.04 (p=1.94x10-41) 1.02 (p=1.39x10-7) 
WHI (Whites) 1.04 (p=2.61x10-43) 1.02 (p=2.77x10-7) 
WHI (Blacks) 1.04 (p=3.46x10-40) 1.02 (p=7.42x10-7) 
WHI (Hispanics) 1.04 (p=4.29x10-41) 1.02 (p=6.17x10-7) 
NAS 1.04 (p=3.91x10-40) 1.02 (p=2.42x10-7) 
InCHIANTI 1.04 (p=1.98x10-41) 1.02 (p=7.38x10-7) 
Rotterdam 1.04 (p=4.35x10-41) 1.02 (p=2.16x10-7) 
KORA 1.04 (p=1.93x10-39) 1.02 (p=3.76x10-7) 
TwinsUK 1.04 (p=3.76x10-41) 1.02 (p=4.66x10-7) 
The  table  reports  hazards  ratios  and  corresponding  p‐values  based  on  a  Cox 
regression.  The  fully  adjusted model  includes  the  following  covariates:  body mass 
index, educational level, alcohol intake, smoking pack‐years, prior history of diabetes, 
prior  history  of  cancer,  hypertension  status,  self‐reported  recreational  physical 
activity.  
  






























































































































fixed‐effect model weighted by  inverse variance  (implemented  in  the metafor R package  [30]).  (A) This measure of age
acceleration is based on Hannum et al [1]. Specifically, we estimated the age using the 71 CpGs and coefficient values from







body mass  index  (category), educational  level  (category), alcohol  intake, smoking pack years, prior history of diabetes, prior history of




































article  except  that  it  uses  a  random‐effects  meta‐analysis  (DerSimonian‐Laird)  instead  of  a  fixed‐effects  model.  A  univariate  Cox
regression model was  used  to  relate  the  censored  survival  time  (time  to  all‐cause mortality)  to  (A)  the  universal measure  of  age
acceleration (AgeAccel), (B) intrinsic epigenetic age acceleration (IEAA), (C) extrinsic epigenetic age acceleration (EEAA). To combine the
coefficient estimates  from  the  respective studies  into a single estimate, we applied  the DerSimonian‐Laird  random effects model. The
sub‐title of each plot reports the meta‐analysis p‐value and a heterogeneity test p‐value (Cochran's Q‐test). 
